Hibercell, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2019-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.hibercell.com
Efficacy/Safety of Imprime PGG With Cetuximab & Paclitaxel/Carboplatin Therapy in Pts With Untreated Advanced Non-Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- NSCLC
- Interventions
- First Posted Date
- 2009-04-03
- Last Posted Date
- 2016-11-29
- Lead Sponsor
- HiberCell, Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT00874848
- Locations
- 🇺🇸
Allison Cancer Center, Midland, Texas, United States
🇩🇪Municipal Clinic Frankfurt Hoescht, Frankfurt, Germany
🇺🇸Mary Crowley Medical Research Center, Dallas, Texas, United States
Efficacy/Safety of Imprime PGG® Injection With Bevacizumab and Paclitaxel/Carboplatin in Patients With Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)
Phase 2
Completed
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2009-04-02
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- HiberCell, Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT00874107
- Locations
- 🇺🇸
Gabrail Cancer Center, Canton, Ohio, United States
🇺🇸Highlands Oncology Group, Fayetteville, Arkansas, United States
🇺🇸University of Texas Health Science Center, San Antonio, San Antonio, Texas, United States
Safety/Efficacy Study of Imprime PGG With Cetuximab in Patients With Recurrent/Progressive Colorectal Carcinoma
Phase 1
Completed
- Conditions
- Recurrent Colorectal CarcinomaProgressive Colorectal Carcinoma
- Interventions
- Biological: Safety and efficacy of escalating dosesBiological: Safety and efficacy of escalating doses.Biological: Imprime PGG 2 mg/kgBiological: Imprime PGG 4 mg/kgBiological: Imprime PGG 6mg/kg
- First Posted Date
- 2007-10-17
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- HiberCell, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT00545545
- Locations
- 🇵ðŸ‡
Medical City, Makati City, Philippines
🇵ðŸ‡Philippine General Hospital, Manila, Philippines
Phase I/II, Randomized, Double-Blind, Study of the Progenitor Cell Mobilizing Effects of Imprime PGGâ„¢ Injection Administered at Varied Dosing Regimens With G-CSF Versus G-CSF Alone
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Biological: Imprime PGG TM for Injection
- First Posted Date
- 2007-10-11
- Last Posted Date
- 2007-10-11
- Lead Sponsor
- HiberCell, Inc.
- Target Recruit Count
- 66
- Registration Number
- NCT00542529
Multiple-Dose, Dose-Escalation Safety, Pharmacodynamics, and Pharmacokinetics Study of Imprime PGGâ„¢ Injection
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Biological: Imprime PGG TM for Injection
- First Posted Date
- 2007-10-11
- Last Posted Date
- 2007-10-11
- Lead Sponsor
- HiberCell, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT00542464
Phase Ia Dose-Escalation Safety, Pharmacodynamic and Pharmacokinetic Study of Imprime PGGâ„¢ Injection
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Biological: Imprime PGG
- First Posted Date
- 2007-10-11
- Last Posted Date
- 2007-10-11
- Lead Sponsor
- HiberCell, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT00542217
© Copyright 2025. All Rights Reserved by MedPath